Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States.
Vaccine Research and Development Center, Department of Physiology and Biophysics, University of California, Irvine, CA 92697, United States.
Cell Immunol. 2023 Apr;386:104691. doi: 10.1016/j.cellimm.2023.104691. Epub 2023 Feb 16.
COVID-19 has caused significant morbidity and mortality worldwide but also accelerated the clinical use of emerging vaccine formulations. To address the current shortcomings in the prevention and treatment of SARS-CoV-2 infection, this study developed a novel vaccine platform that closely mimics dendritic cells (DCs) in antigen presentation and T-cell stimulation in a cell-free and tunable manner. Genetically engineered DCs that express the SARS-CoV-2 spike protein (S) were chemically converted into extracellular blebs (EBs). The resulting EBs elicited potentially protective humoral immunity in vivo, indicated by the production of antibodies that potently neutralized S-pseudotyped virus, presenting EBs as a promising and safe vaccine.
COVID-19 已在全球范围内造成了大量的发病率和死亡率，但也加速了新兴疫苗制剂的临床应用。为了解决目前 SARS-CoV-2 感染预防和治疗的不足，本研究开发了一种新型疫苗平台，以无细胞且可调节的方式模拟树突状细胞（DC）在抗原呈递和 T 细胞刺激中的作用。表达 SARS-CoV-2 刺突蛋白（S）的基因工程化 DC 被化学转化为细胞外泡（EBs）。体内实验表明，所产生的 EBs 引起了潜在的保护性体液免疫，产生了能够有效中和 S 假型病毒的抗体，提示 EBs 作为一种有前途且安全的疫苗。
